» Articles » PMID: 34175839

Identification of Differentially Expressed Genes-related Prognostic Risk Model for Survival Prediction in Breast Carcinoma Patients

Overview
Specialty Geriatrics
Date 2021 Jun 27
PMID 34175839
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Since the imbalance of gene expression has been demonstrated to tightly related to breast cancer (BRCA) genesis and growth, common genes expressed of BRCA were screened to explore the essence in-between. In current work, most common differentially expressed genes (DEGs) in various subtypes of BRCA were identified. Functional enrichment analysis illustrated the driving factor of deactivation of the cell cycle and the oocyte meiosis, which critically triggers the development of BRCA. Herein, we constructed a 12-gene prognostic risk model relative to differential gene expression. Subsequently, the K-M curves, analysis on time-ROC curve and Cox regression were performed to assess this risk model by determining the respective prognostic value, and the prediction performance were ascertained for both training and validation cohorts. In addition, multivariate Cox regression was analysed to reveal the independence between risk score and prognostic stage, and the accuracy and sensitivity of prognosis are particularly improved after clinical indicators are included into the analysis. In summary, this study offers novel insights into the imbalance of gene expression within BRCA, and highlights 12 selected genes associated with patient prognosis. The risk model can help individualize treatment for patients at different risks, and propose precise strategies and treatments for BRCA therapy.

Citing Articles

Effect of microRNA-141-3p, E2F3, CDK3, and KAT2B overexpression on histologic tumor grade and metastasis status in untreated breast cancer tissues.

Ebrahimian Vargahan S, Barati M, Roudbari M, Eini M, Hosseini A Bioimpacts. 2025; 15:30032.

PMID: 39963567 PMC: 11830142. DOI: 10.34172/bi.30032.


Targeting protein tyrosine phosphatase non-receptor type 6 (PTPN6) as a therapeutic strategy in acute myeloid leukemia.

Wang X, Li Z, Shen J, Liu L Cell Biol Toxicol. 2024; 41(1):11.

PMID: 39707066 PMC: 11662038. DOI: 10.1007/s10565-024-09965-3.


The role of NOP58 in prostate cancer progression through SUMOylation regulation and drug response.

Guo W, Zong S, Liu T, Chao Y, Wang K Front Pharmacol. 2024; 15:1476025.

PMID: 39494345 PMC: 11530994. DOI: 10.3389/fphar.2024.1476025.


Bioinformatics and network biology approach to identifying type 2 diabetes genes and pathways that influence the progression of breast cancer.

Sarkar M, Mia M, Al Amin M, Hossain M, Islam M Heliyon. 2023; 9(5):e16151.

PMID: 37234659 PMC: 10205526. DOI: 10.1016/j.heliyon.2023.e16151.

References
1.
Lin W, Chiu K, Chang H, Lee K, Tai T, Chuang L . Molecular scanning of the human sorbin and SH3-domain-containing-1 (SORBS1) gene: positive association of the T228A polymorphism with obesity and type 2 diabetes. Hum Mol Genet. 2001; 10(17):1753-60. DOI: 10.1093/hmg/10.17.1753. View

2.
Balachandran V, Gonen M, Smith J, DeMatteo R . Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015; 16(4):e173-80. PMC: 4465353. DOI: 10.1016/S1470-2045(14)71116-7. View

3.
Wang Y, Leng H, Chen H, Wang L, Jiang N, Huo X . Knockdown of UBE2T Inhibits Osteosarcoma Cell Proliferation, Migration, and Invasion by Suppressing the PI3K/Akt Signaling Pathway. Oncol Res. 2016; 24(5):361-369. PMC: 7838603. DOI: 10.3727/096504016X14685034103310. View

4.
Bieche I, Vacher S, Lallemand F, Tozlu-Kara S, Bennani H, Beuzelin M . Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidy. Mol Cancer. 2011; 10:23. PMC: 3058099. DOI: 10.1186/1476-4598-10-23. View

5.
Lu Y, Rosenfeld R, Simon I, Nau G, Bar-Joseph Z . A probabilistic generative model for GO enrichment analysis. Nucleic Acids Res. 2008; 36(17):e109. PMC: 2553574. DOI: 10.1093/nar/gkn434. View